Welcome to our dedicated page for Eyepoint Pharmac news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on Eyepoint Pharmac stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical innovator advancing sustained-release therapies for retinal diseases through its proprietary Durasert E technology. This page provides investors and industry professionals with a comprehensive repository of official company news, including press releases, clinical trial updates, and strategic developments.
Access timely updates on EYPT’s progress in ocular drug delivery, including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures you stay informed about critical developments in treatments for wet AMD, diabetic macular edema, and other retinal conditions.
Key updates include progress on DURAVYU™ clinical trials, licensing agreements, financial disclosures, and scientific innovations. All content is sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to EyePoint’s latest developments. Check back regularly for authoritative updates on one of ophthalmology’s most promising sustained-release therapy developers.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the granting of non-statutory stock options to four new employees as inducement awards outside the company's 2023 Long-Term Incentive Plan, adhering to NASDAQ Listing Rule 5635(c)(4). The grants, approved by the Compensation Committee, involve options to purchase a total of 44,200 shares of common stock. These options were issued on May 15, 2024, at an exercise price of $12.94 per share, the closing price of the stock on that date. The options have a ten-year term and vest over four years, with 25% vesting after the first year and the rest in monthly installments over the next three years, contingent on continued employment.
EyePoint Pharmaceuticals reported financial results for the first quarter of 2024 and highlighted recent corporate developments. The company has $299 million in cash and investments as of March 31, 2024, ensuring cash runway through Phase 3 trials for DURAVYU for wet AMD in 2026. Despite the Phase 2 PAVIA trial not meeting the primary endpoint, DURAVYU showed a biologic effect in patients with NPDR. EyePoint plans to initiate the Phase 3 LUGANO trial for DURAVYU in wet AMD and present Phase 2 VERONA trial data in 2025.
EyePoint Pharmaceuticals announced topline results of the Phase 2 PAVIA trial evaluating DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR). Although the trial did not meet the primary endpoint, DURAVYU demonstrated a favorable safety profile and potential in reducing NPDR progression at nine months. The Company plans to review full 12-month data to determine the future path for DURAVYU. Dr. Duker expressed optimism for DURAVYU's potential as a maintenance therapy for wet AMD patients based on positive data from DAVIO 2.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
